Sanofi reorganizes the management structure and 4 senior executives leave!

Compiling coco In December 2019, Paul Hudson, CEO of Sanofi, proposed an ambitious plan to reshape the company, and at the same time, he said that the company's management structure should be simplified Recently, he took a big step towards fulfilling his promise - kicking four members out of the executive team According to Bloomberg news on February 12, Hudson announced that the company's management will be reorganized, and four executives will leave They are Ameet nathwani, medical and digital officer, Dieter weinand, head of primary health care business, Dominique Carouge, head of business transformation, and Kathleen trending, head of foreign affairs It is not known whether "separation" means immediate effect or elimination within a period of time A spokeswoman for Sanofi confirmed in an email in response to the fiercepharma website that four executives would leave Ameet nathwani was appointed chief medical officer in 2016 and chief digital officer in 2019 One of his major initiatives is a partnership with Google that focuses on developing new technologies such as digital therapy and helping Sanofi integrate AI into its business It may not be surprising that executives leave A few days ago, Hudson told Sanofi's fourth quarter of 2019 earnings conference call that he intended to reduce the number of executive committee members from 14 to 10 before restructuring It is hoped that more central expertise will be allocated to our business units and that accountability will be strengthened As Bloomberg reports, the idea is to speed up Sanofi's decision-making process Moreover, Hudson clearly thought of improving Sanofi's digital capabilities in the strategic adjustment In a previous conference call, he said the reason for this was that the company was lagging behind in terms of internal digital understanding and language skills Moreover, the company will not choose to mix the chief medical officer and the digital officer, and pay more attention to the digital officer In the short to medium term, this role will tend to help companies improve user experience and data science management △ Paul Hudson Hudson has always been a champion of using technology to promote drug discovery and development At Novartis, he was a key leader in implementing AI programs for sales people Since taking over from Sanofi last fall, he has always said that he wants every employee to master decision-making skills backed by data and analysis And Hudson doesn't think pharmaceutical companies need to work with technology giants to do it Indeed, Sanofi withdrew from its partnership with verily, a sister company of Google, in December 2019 The two companies established ondoo, a diabetes partner, in 2016, with each company investing $500 million Now, as diabetes research and development is cut, Sanofi will restructure the joint venture to continue to provide financial support, but no longer participate in operations In December 2019, Hudson announced that the company will focus on promoting efforts in six key areas, including hemophilia, oncology, hematology, rare diseases and neurology, but excluding diabetes and cardiovascular diseases This strategic adjustment is expected to save the company about $2 billion There is no doubt that Hudson's moves are key to a big goal: refocusing the company on high growth Sanofi currently attaches great importance to the anti-inflammatory drug dupixent, which is used in the treatment of asthma, eczema and nasal polyps Hudson expects dupixent's sales to grow from 2.07 billion euros in 2019 to 10 billion euros in 2020 Sanofi will no longer pay more attention to the business that makes the company famous The diabetes and cardiovascular business has been struggling for many years, but the latest data in fy2019 shows that the diabetes business accounts for about 13% of its total revenue, down nearly 10% from 2018 Investors are also looking forward to Hudson's innovation In a report released in January, vantage analysts pointed out that 78% of the company's sales in 2019 came from products that had been on the market for more than 10 years If Hudson's reforms don't work, Sanofi will be almost as dependent on "old drugs" within five years This comprehensive strategic adjustment marks Sanofi's turn.